The October issue of the innoVation series is a special workshop report of the FDA (Pang et al., 2019) on improving cardiotoxicity assessment with human-relevant platforms.
In detail, the urgent need to integrate human-relevant platforms/approaches into drug development to reduce cardiovascular safety liabilities were discussed, including potential regulatory applications of human-derived cardiomyocytes and future directions in employing human-relevant platforms to fill gaps and overcome barriers and challenges in preclinical cardiovascular safety assessment.
Read the full article here.
